Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Colin F Spraggs"'
Autor:
Lini N. Pandite, Neil Kaplowitz, Thomas Powles, Andreas du Bois, Hiroomi Tada, Matthew R. Nelson, Colin F. Spraggs, Ionel Mitrica, Linda P. Briley, Sandy Stinnett, Dana J. Fraser, Karen S. King, Zhengyu Xue, Liling Warren, Alan P. Graves, Chris Carpenter, Xiaojing Wang, Toby Johnson, Chun-Fang Xu
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib-treated patients. We conducted pharmacogenetic analyses to explore mechanistic in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3839491b219ef58d50509358882ee7ba
https://doi.org/10.1158/1078-0432.c.6524039.v1
https://doi.org/10.1158/1078-0432.c.6524039.v1
Autor:
Lini N. Pandite, Neil Kaplowitz, Thomas Powles, Andreas du Bois, Hiroomi Tada, Matthew R. Nelson, Colin F. Spraggs, Ionel Mitrica, Linda P. Briley, Sandy Stinnett, Dana J. Fraser, Karen S. King, Zhengyu Xue, Liling Warren, Alan P. Graves, Chris Carpenter, Xiaojing Wang, Toby Johnson, Chun-Fang Xu
Supplementary Table S1. Summary of eight pazopanib (monotherapy) clinical studies included in the discovery pharmacogenetic liver toxicity analysis Supplementary Table S2. Summary of 23 pazopanib clinical studies included in the confirmatory pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84251c105feab3d723a3f5866015ff3d
https://doi.org/10.1158/1078-0432.22458767
https://doi.org/10.1158/1078-0432.22458767
Autor:
Julie R. Gralow, Ajay O. Mehta, L. P. Briley, Lyndsay Harris, L. Warren, E. A. Perez, Georgia Demetriou, Julie Byrne, Masakazu Toi, Colin F. Spraggs, Martine Piccart, JoAnne Zujewski, Zeba Aziz, A Armour, S. Ahmed, Martin Andersson, Laura R. Parham, L. S. Williams, Z-f Jiang, N. Jackson, R. Crescenzo, D. J. Fraser
Publikováno v:
The Pharmacogenomics Journal. 18:480-486
HLA-DRB1*07:01 allele carriage was characterised as a risk biomarker for lapatinib-induced liver injury in a large global study evaluating lapatinib, alone and in combination with trastuzumab and taxanes, as adjuvant therapy for advanced breast cance
Autor:
Jeff Legos, Bijoyesh Mookerjee, Kijoung Song, Colin F. Spraggs, Diptee A. Kulkarni, Linda Briley, Christine Dabrowski, Karen S. King
Publikováno v:
Pharmacogenomics. 17:459-462
Aim: Pyrexia is a common adverse event (AE) on dabrafenib treatment (monotherapy or combination with trametinib). Since germline SNPs and HLA alleles are implicated in drug-induced AEs, this study investigated their association with pyrexia. Patients
Autor:
Linda P. Briley, Lini Pandite, Dana Fraser, Karen S. King, Xiaojing Wang, Sandy Stinnett, Colin F Spraggs, Alan P. Graves, Andreas du Bois, Hiroomi Tada, Ionel Mitrica, Matthew R. Nelson, Neil Kaplowitz, Zhengyu Xue, Thomas Powles, Liling Warren, Christopher L. Carpenter, Toby Johnson, Chun-Fang Xu
Publikováno v:
Clin Cancer Res
Purpose: Pazopanib is an effective treatment for advanced renal cell carcinoma and soft-tissue sarcoma. Transaminase elevations have been commonly observed in pazopanib-treated patients. We conducted pharmacogenetic analyses to explore mechanistic in
Publikováno v:
CHEMICAL RESEARCH IN TOXICOLOGY
It is hypothesized that lapatinib-induced liver injury is caused by HLA-mediated antigen presentation to CD4 positive T cells. However, analysis of PBMC and cloned T-cells from patients with HLA-DRB1*07:01-restricted lapatinib-induced liver injury re
Autor:
Karen S. King, Colin F. Spraggs, Paul J. Newcombe, Gil McVean, Zamin Iqbal, A J Slater, Matthew R. Nelson, Alexander T. Dilthey, Judong Shen, Linda P. Briley, Li Li, Charles J. Cox, Laura R. Parham
Publikováno v:
The Pharmacogenomics Journal
Lapatinib is associated with a low incidence of serious liver injury. Previous investigations have identified and confirmed the Class II allele HLA-DRB1*07:01 to be strongly associated with lapatinib-induced liver injury; however, the moderate positi
Autor:
Shannon K. McDonnell, Joan Curran, Dianne M. Finkelstein, Lon R. Cardon, Charles J. Cox, E. Rappold, Laura R. Parham, Bent Ejlertsen, Daniel J. Schaid, Colin F. Spraggs, Paul E. Goss
Publikováno v:
Journal of Clinical Oncology. 32:2296-2303
Purpose Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously associated major histocompatibility complex (MHC) variants as predictors of risk of liver
Autor:
Linda P. Briley, Laura R. Parham, Paul E. Goss, Karen S. King, E. Rappold, Julie Byrne, Colin F. Spraggs
Publikováno v:
Pharmacogenomics. 16:1227-1229
Rash is a common side effect of lapatinib treatment. Since human leukocyte antigen (HLA) alleles have been implicated in multiple drug-induced cutaneous reactions, this study investigated the association of HLA alleles with lapatinib-induced rash. 11
Autor:
A. du Bois, Laura R. Parham, L. P. Briley, Mark W. Russo, Colin F. Spraggs, Toby Johnson, Kijoung Song, Chun-Fang Xu, Hiroomi Tada
Publikováno v:
Annals of Oncology. 26:1515-1517